New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 26, 2011
07:46 EDTCLSNCelsion initiated with an Outperform at Rodman & Renshaw
Target $6.
News For CLSN From The Last 14 Days
Check below for free stories on CLSN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
06:57 EDTCLSNCelsion updates OS results from HEAT study of ThermoDox
Celsion announced that updated results from the 701 patient HEAT Study post-hoc analysis, as well as a review of the final study design of the Phase III OPTIMA Study, which both explore ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation, or RFA, for the treatment of hepatocellular carcinoma, or HCC, or primary liver cancer, were presented at the 5th European Conference on Interventional Oncology, or ECIO, on April 24 in Berlin, Germany. Data from the latest HEAT Study post-hoc analysis as of March 31 suggest that ThermoDox may markedly improve overall survival, or OS, compared to RFA control, in patients whose lesions undergo RFA treatment for 45 minutes or more. These findings apply to patients with single HCC lesions from both size cohorts of the HEAT study and represent a subgroup of 285 patients. For this subgroup, clinical results indicate a 50% improvement in overall survival, a Hazard Ratio of 0.666, and a p-Value of 0.06. It is important to note that the median overall survival for this subgroup has not yet been reached.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use